QualityDipStocks / Health Care · Medical instruments
Boston Scientific BSX
Deep dip with a setup armed: a close above $43.92 triggers it. 60% below its 52-week high.
A quality company trading well below our fair value estimate.
- Fair value est.
- $75.83+81%
- Market Value
- forming
- Off 52-wk high
- −60%
- Risk vs market
- Lowbeta 0.14
5 bullish · 1 bearish See why
Key levels
Every level vs today’s $41.98
- Stopreference, not an order$39.57−5.7%
- 52-wk lowlowest close, 1 year$41.58−1.0%
- PriceFri Oct 30 close$41.98you are here
- Triggerclose above fires the setup$43.92+4.6%
- Fair value est.base case$75.83+80.6%
- 52-wk highhighest close, 1 year$104.98+150.1%
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 15.0% ±2 points. Bear = 10.5% and 13.0%; bull = 8.5% and 17.0% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price is below even the bear case.
What the price implies To be worth today’s price, BSX’s free cash flow would need to grow about 4% a year for five years; our estimate uses 15%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much BSX moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Has moved mostly independently of the market, but its own price swings are 3.0× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.14
- Volatility
- 39% vs 13% SPY
- Correlation SPY
- 0.05
- Correlation QQQ
- −0.02
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
ValuationOur DCF fair value estimate is $75.83, 81% above the price.
ValuationP/E of 16.9× is 71% below its own average of 58.2× at the last 3 fiscal year-ends.
GrowthDiluted EPS grew 55% to $1.94 in FY2025.
TechnicalA company that passes our quality screen, now 60% off its 52-week high (deep dip).
SetupA capitulation-reversal setup is armed: a close above $43.92 triggers it, with a reference stop at $39.57.
Top bearish points 1 of 5
Balance sheetDebt rose 30% to $11.1B from FY2023 to FY2025.
Who’s talking about it
Notable investors, executives, analysts and public figures on Boston Scientific in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Medical instruments
All fundamentals
P/E 16.9 · FCF yield 5.9% · ROE 16%
Valuation
- P/E
- 16.9×3-yr-end avg 58.2× · Health Care median 29.2×
- Price / FCF
- 17.1×
- FCF yield
- 5.9%
- EV / EBITDA
- 13.0×
- Price / sales
- 2.95×
- Price / book
- 2.48×
- Market cap
- $61.9Bprice × diluted shares
- Enterprise value
- $72.3B
Growth
- Revenue, 12 months
- $21.0B
- Sales growth, 12 months
- +13.5%vs the 12 months before
- Sales growth, 3 yrs
- +16.5%/yrfrom FY2022
- Diluted EPS, 12 months
- $2.47
- EPS growth, last FY
- +55.2%
- Net income, 12 months
- $3.7B
- Net income growth
- +47%12 months vs before
Profitability
- Gross margin
- 69.9%
- Operating margin
- 19.8%
- Net margin
- 17.5%
- FCF margin
- 17.3%
- Return on equity
- 16%
- Return on invested capital
- 11%
Balance sheet
- Cash & short-term inv.
- $539M
- Total debt
- $10.9B
- Net cash
- −$10.4B
- Debt / equity
- 0.44×
- Interest coverage
- 11.4×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- $3.6B
- FCF growth, 12 months
- +4%
- Dividend yield
- n/ano dividend payments tagged
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- −1.3%diluted shares vs a year ago
- Stock-based comp
- $320M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Boston Scientific’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
DCF $75.83 · FCF value $55.95
Assumes 15.0% growth for 5 years (revenue grew 16.5% a year FY22–FY25; capped at 15%), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $2.46 a share (trailing 12 months to Jun 30, 2026), from the 10-Q filed Aug 3, 2026.
Setup & signals
Armed · trigger $43.92
Momentum & 52-week range
RSI 39 · 5 days −8.1%
The business
FCF $3.3B · Sales +12%
- Free cash flow, 12 months$3.3B
- Free-cash-flow yield5.3%
- Free-cash-flow margin16%
- Gross margin69%
- Operating margin21%
- Return on invested capital9%
- Return on equity15%
- Sales growth (latest quarter vs year-ago quarter)+12%
- Net debt / EBITDA1.9×
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
Get a text when BSX fires a reversal signal
One text when a published rule fires on BSX or any of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.